PRA launches pediatric site network

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/KatarzynaBialasiewicz)
(Image: Getty/KatarzynaBialasiewicz)

Related tags: Pediatrics, Pra health sciences, Clinical development

PRA Health Sciences has launched a new site network focused on improving pediatric clinical development and access to novel medicines in this special patient population.

The new Pediatric Site Network (PSN) is a series of pediatric research centers around the world, which according to PRA, will it to “improve pediatric clinical development and enhance access to novel medicines for the pediatric population.”

The contract research organization (CRO) has formalized relationships with centers in the EU, US, and Israel, and has plans to expand to Latin America and the Asia Pacific.

The “focal point and repository”​ for the company’s global pediatrics knowledge is its Center for Pediatric Clinical Development, it said.

PRA launched the center in May 2017, at which time the center’s VP Mark Sorrentino, MD, said the next step would be to form a global network.

Read: PRA looks to bring child-friendly solutions to pediatric clinical trials

“Operationalizing patient- and family-centered pediatric clinical trials is a complex process in that it requires careful consideration of study design and logistical challenges unique to this vulnerable population,”​ said Kirsten Sherman Cervati, senior director, Center for Pediatric Clinical Development, lead, Pediatric Site Network.

“Through our Pediatric Site Network we have opportunity to augment our existing pediatric expertise with insights from research minded thought leaders with the shared goal of advancing safe and effective treatment options within the pediatric space,”​ she told us.

More than 70% of medications are prescribed to children off label, though demand to conduct clinical trials to address this gap has increased significantly over the past 20 years, said Sherman Cervati.

Additionally, both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have published legislation requiring written plans for all medications under investigation to be assessed in children.


On the PRA’s recent Q3 earnings call​, CEO Colin Shannon said the company has been looking at “a few things” over seas and contemplating adding to the business, though nothing is expected immediately.

“We see some market opportunities that we might want to take advantage of; and there could potentially be tuck-in acquisitions [that] would give us the capability to take advantage of some of our data solutions,” ​ he said.

Shannon explained that PRA is looking to expand its capabilities in other markets, a lot of which can be done organically. “We're still building out some areas in Asia, and we're still [seeing] a lot of room to expand that significantly and we're working through that just now. I don't see that as being acquisitions, I do see that as more organic growth,” ​ he added

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more